Piper Jaffray Companies restated their buy rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research note published on Monday morning. They currently have a $540.00 target price on the biopharmaceutical company’s stock.
Several other research firms have also recently weighed in on REGN. Bank of America Corporation reiterated a buy rating and set a $593.00 price objective (up from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. BMO Capital Markets reissued a market perform rating and set a $484.00 target price (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Barclays PLC reissued an equal weight rating and set a $450.00 target price (up previously from $400.00) on shares of Regeneron Pharmaceuticals in a research note on Saturday, July 22nd. Canaccord Genuity set a $522.00 target price on shares of Regeneron Pharmaceuticals and gave the company a buy rating in a research note on Friday, July 28th. Finally, Citigroup Inc. reissued a buy rating and set a $575.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, September 7th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $481.49.
Regeneron Pharmaceuticals (REGN) opened at $386.30 on Monday. Regeneron Pharmaceuticals has a 52-week low of $340.09 and a 52-week high of $543.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. The firm has a market cap of $42,176.78, a P/E ratio of 34.08, a price-to-earnings-growth ratio of 1.55 and a beta of 1.56.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping the consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. During the same period in the previous year, the company posted $3.13 EPS. The company’s quarterly revenue was up 23.0% compared to the same quarter last year. equities analysts anticipate that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/11/16/regeneron-pharmaceuticals-regn-buy-rating-reiterated-at-piper-jaffray-companies.html.
In other Regeneron Pharmaceuticals news, Director Charles A. Baker sold 2,000 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Sanofi bought 166,415 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were purchased at an average cost of $480.93 per share, with a total value of $80,033,965.95. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 76,651 shares of company stock valued at $36,285,438. 10.80% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. Fieldpoint Private Securities LLC acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $130,000. Sterling Investment Advisors Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 11.2% during the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 28 shares during the period. FNY Partners Fund LP increased its holdings in shares of Regeneron Pharmaceuticals by 200.0% during the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the period. Alpha Windward LLC increased its holdings in shares of Regeneron Pharmaceuticals by 0.3% during the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 1 shares during the period. Finally, IFP Advisors Inc increased its holdings in shares of Regeneron Pharmaceuticals by 33.2% during the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 96 shares during the period. 67.80% of the stock is owned by hedge funds and other institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.